279 related articles for article (PubMed ID: 30374743)
1. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.
Lückerath K; Wei L; Fendler WP; Evans-Axelsson S; Stuparu AD; Slavik R; Mona CE; Calais J; Rettig M; Reiter RE; Herrmann K; Radu CG; Czernin J; Eiber M
EJNMMI Res; 2018 Oct; 8(1):96. PubMed ID: 30374743
[TBL] [Abstract][Full Text] [Related]
2. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
[TBL] [Abstract][Full Text] [Related]
3. Establishing
Fendler WP; Stuparu AD; Evans-Axelsson S; Lückerath K; Wei L; Kim W; Poddar S; Said J; Radu CG; Eiber M; Czernin J; Slavik R; Herrmann K
J Nucl Med; 2017 Nov; 58(11):1786-1792. PubMed ID: 28546332
[TBL] [Abstract][Full Text] [Related]
4. Impact of [
Groener D; Wichert J; Adams M; Mader N; Klimek K; Nguyen Ngoc C; Baumgarten J; Happel C; Mandel P; Chun FKH; Tselis N; Grünwald F; Sabet A
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568694
[TBL] [Abstract][Full Text] [Related]
5. Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer.
DiPippo VA; Nguyen HM; Brown LG; Olson WC; Vessella RL; Corey E
Prostate; 2016 Feb; 76(3):325-34. PubMed ID: 26585210
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer.
Stuparu AD; Capri JR; Meyer CAL; Le TM; Evans-Axelsson SL; Current K; Lennox M; Mona CE; Fendler WP; Calais J; Eiber M; Dahlbom M; Czernin J; Radu CG; Lückerath K; Slavik R
J Nucl Med; 2021 Jul; 62(7):989-995. PubMed ID: 33277393
[TBL] [Abstract][Full Text] [Related]
7. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.
Current K; Meyer C; Magyar CE; Mona CE; Almajano J; Slavik R; Stuparu AD; Cheng C; Dawson DW; Radu CG; Czernin J; Lueckerath K
Clin Cancer Res; 2020 Jun; 26(12):2946-2955. PubMed ID: 31932492
[TBL] [Abstract][Full Text] [Related]
8. Value of Combined PET Imaging with [
Khreish F; Ribbat K; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Schreckenberger M; Ezziddin S; Rosar F
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439287
[TBL] [Abstract][Full Text] [Related]
9. In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2
Prasad V; Huang K; Prasad S; Makowski MR; Czech N; Brenner W
Front Oncol; 2021; 11():578093. PubMed ID: 33816225
[TBL] [Abstract][Full Text] [Related]
10. Baseline [
Groener D; Schneider S; Baumgarten J; Happel C; Klimek K; Mader N; Nguyen Ngoc C; Wichert J; Mandel P; Tselis N; Grünwald F; Sabet A
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672421
[TBL] [Abstract][Full Text] [Related]
11. Outcome and safety of rechallenge [
Yordanova A; Linden P; Hauser S; Meisenheimer M; Kürpig S; Feldmann G; Gaertner FC; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1073-1080. PubMed ID: 30474706
[TBL] [Abstract][Full Text] [Related]
12. PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study.
Banda A; Privé BM; Allach Y; Uijen MJM; Peters SMB; Loeff CC; Gotthardt M; Muselaers CHJ; Witjes JA; van Oort IM; Sedelaar JPM; Westdorp H; Mehra N; Khreish F; Ezziddin S; Sabet A; Kreissl MC; Winkens T; Seifert P; Janssen MJR; van Gemert WAM; Nagarajah J
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612293
[TBL] [Abstract][Full Text] [Related]
13. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
14. The
Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
[TBL] [Abstract][Full Text] [Related]
15. PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under
Widjaja L; Werner RA; Ross TL; Bengel FM; Derlin T
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208246
[No Abstract] [Full Text] [Related]
16. Renal Safety of [
Rosar F; Kochems N; Bartholomä M; Maus S; Stemler T; Linxweiler J; Khreish F; Ezziddin S
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205686
[No Abstract] [Full Text] [Related]
17. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
18. Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [
Rosar F; Bader H; Bartholomä M; Maus S; Burgard C; Linxweiler J; Khreish F; Ezziddin S
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681671
[TBL] [Abstract][Full Text] [Related]
19. [
Truckenmueller P; Graef J; Scheel M; Vajkoczy P; Capper D; Kaul D; Furth C; Amthauer H; Brenner W; Onken JS
Front Oncol; 2022; 12():980058. PubMed ID: 36119502
[TBL] [Abstract][Full Text] [Related]
20. [PSMA radioligand therapy in patients with advanced prostate cancer].
Bögemann M; Herrmann K; Radtke JP; Rahbar K
Urologe A; 2020 Jun; 59(6):680-686. PubMed ID: 32333064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]